Comments on: The Greater Boston Diabetes Cluster http://www.xconomy.com/boston/2009/02/09/the-greater-boston-diabetes-cluster-here%e2%80%99s-the-list/ Business + Technology in the Exponential Economy Sat, 11 Feb 2012 09:07:58 +0000 hourly 1 http://wordpress.org/?v=3.0.4 By: Scott http://www.xconomy.com/boston/2009/02/09/the-greater-boston-diabetes-cluster-here%e2%80%99s-the-list/comment-page-1/#comment-266167 Scott Thu, 09 Dec 2010 20:07:10 +0000 http://www.xconomy.com/?p=11726#comment-266167 You did not include Biodel, Inc., which is based in Danbury, Connecticut. At present, BIOD has a rapid-acting version of biosynthetic human insulin pending FDA approval they are calling Linjeta(TM) which is not an insulin analogue, but removes zinc from the insulin molecule using ethylenediaminetetraacetic acid (usually abbreviated as "EDTA") which destabilizes the hexamer of the insulin molecule; then, by adding citric acid, which masks the surface charges and further destabilizes the insulin molecule so that it does not form hexamers as it would normally when injected into the skin without these modifications. Although it was not approved in October 2010 as many had anticipated, the company's business plan always presumed the product would not be sold until 2011 anyway. Beyond that, BIOD has several interesting items beyond Linjeta in its pipeline including an adjustable basal insulin analogue, and a stable form of the counterregulatory hormone glucagon, as well as a sublingual form of insulin that can be taken orally. You did not include Biodel, Inc., which is based in Danbury, Connecticut. At present, BIOD has a rapid-acting version of biosynthetic human insulin pending FDA approval they are calling Linjeta(TM) which is not an insulin analogue, but removes zinc from the insulin molecule using ethylenediaminetetraacetic acid (usually abbreviated as “EDTA”) which destabilizes the hexamer of the insulin molecule; then, by adding citric acid, which masks the surface charges and further destabilizes the insulin molecule so that it does not form hexamers as it would normally when injected into the skin without these modifications.

Although it was not approved in October 2010 as many had anticipated, the company’s business plan always presumed the product would not be sold until 2011 anyway. Beyond that, BIOD has several interesting items beyond Linjeta in its pipeline including an adjustable basal insulin analogue, and a stable form of the counterregulatory hormone glucagon, as well as a sublingual form of insulin that can be taken orally.

]]> By: Joel Weinberg http://www.xconomy.com/boston/2009/02/09/the-greater-boston-diabetes-cluster-here%e2%80%99s-the-list/comment-page-1/#comment-45840 Joel Weinberg Tue, 10 Feb 2009 22:25:18 +0000 http://www.xconomy.com/?p=11726#comment-45840 You missed Covidien from Mansfield. They are working hard on educating people about the resolution of type 2 diabetes through gastric bypass surgery. You missed Covidien from Mansfield.
They are working hard on educating people about the resolution of type 2 diabetes through gastric bypass surgery.

]]> By: James Geshwiler http://www.xconomy.com/boston/2009/02/09/the-greater-boston-diabetes-cluster-here%e2%80%99s-the-list/comment-page-1/#comment-45710 James Geshwiler Mon, 09 Feb 2009 17:01:48 +0000 http://www.xconomy.com/?p=11726#comment-45710 Don't forget that the Joslin Diabetes Research Center--one of top in the world--is here as well. http://joslin.org/ Don’t forget that the Joslin Diabetes Research Center–one of top in the world–is here as well. http://joslin.org/

]]>